

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
16 November 2023 (16.11.2023)



(10) International Publication Number

WO 2023/220351 A1

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2023/022007

(22) International Filing Date:
12 May 2023 (12.05.2023)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
63/364,639 13 May 2022 (13.05.2022) US

(71) Applicant: **DICERNA PHARMACEUTICALS, INC.**
[US/US]; 75 Hayden Avenue, Lexington, Massachusetts
02421 (US).

(72) Inventors: **BROWN, Bob, Dale**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **DUDEK, Henryk, T.**; c/o Dicerna Pharmaceu-
ticals, Inc., 75 Hayden Avenue, Lexington, Massachusetts
02421 (US). **CHEONG, Seongmoon**; c/o Dicerna Phar-
maceuticals, Inc., 75 Hayden Avenue, Lexington, Mass-
achusetts 02421 (US). **WANG, Shiyu**; c/o Dicerna Phar-
maceuticals, Inc., 75 Hayden Avenue, c/o 75 Hayden Ave-
nue, Massachusetts 02421 (US). **GRIM, Travis**; c/o Dicer-
na Pharmaceuticals, Inc., 75 Hayden Avenue, Lexington,
Massachusetts 02421 (US). **COSTALES, Matthew Guese**;
c/o Dicerna Pharmaceuticals, Inc., 75 Hayden Avenue,
Lexington, Massachusetts 02421 (US). **JUNG, Maire**; c/o
Dicerna Pharmaceuticals, Inc., 75 Hayden Avenue, Lexing-
ton, Massachusetts 02421 (US).

(74) Agent: **REID, Andrea L.C.** et al.; c/o Dechert LLP, One
International Place, 40th Floor, 100 Oliver Street, Boston,
Massachusetts 02110-2605 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: COMPOSITIONS AND METHODS FOR INHIBITING *SNCA* EXPRESSION

(57) Abstract: Oligonucleotides (e.g., RNAi oligonucleotides) are provided herein that inhibit *SNCA* gene expression, including oligonucleotides conjugated to a targeting ligand (e.g., GalNAC moiety or lipid moiety). Also provided are compositions including the same and uses thereof, particularly uses relating to treating diseases, disorders, and/or conditions associated with *SNCA* gene expression.

WO 2023/220351 A1